We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants Breakthrough Designation to GI Infection Therapy
FDA Grants Breakthrough Designation to GI Infection Therapy
Roseville, Minn.-based Rebiotix has been granted FDA breakthrough therapy status for its lead product RBX2660 to treat recurrent Clostridium difficile infection.